Hypoparathyroidism Treatment Market 2025–2033: Competitive Landscape

According to FutureWise analysis, the Hypoparathyroidism Treatment market in 2025 is US$1.27 billion, and is expected to reach US$2.30 billion by 2033 at a CAGR of 7.71%. The Hypoparathyroidism Treatment market is experiencing growth due to several factors: the increasing prevalence of the disorder, heightened awareness of diagnosis, and a growing adoption of hormone replacement therapies, such as recombinant human parathyroid hormone (rhPTH). This upward trend indicates a rise in diagnosis rates and improved awareness of the condition among healthcare professionals. The expansion of the market is further fueled by the introduction of innovative therapeutics, like recombinant parathyroid hormone therapies, which offer superior disease management compared to traditional calcium and vitamin D supplementation. Additionally, the rising incidence of post-surgical hypoparathyroidism and increased investment in treatments for rare diseases are significant drivers of this trend. Advancements in biologics and supportive regulatory approvals are also accelerating the development of new therapies. Furthermore, rising investments in research for rare endocrine disorders and improved patient access to treatment options are contributing to the ongoing expansion of the market.

Hypoparathyroidism is an endocrine disorder characterized by the insufficient production of parathyroid hormone (PTH) by the parathyroid glands, which are located in the neck. PTH plays a crucial role in maintaining optimal levels of calcium, phosphate, and calcitriol (the active form of Vitamin D) in the blood and bones. This rare condition occurs when the body does not produce enough PTH, leading to imbalanced calcium and phosphorus levels. One of the most common treatments for hypoparathyroidism involves supplementing the body with vitamins and minerals to restore these essential levels. This typically includes taking calcium carbonate pills or high doses of oral Vitamin D.

FutureWise Market Research has released a report that provides an in-depth analysis of the Hypoparathyroidism Treatment Market trends that shall affect the overall market growth.

Request a Free Sample @

https://www.futurewiseresearch.com/contact.aspx?rpt=11324&type=requestsample

By Drug Class

• Parathyroid Hormone
• Natpara
• Others
• Vitamin D Analogue
• Vitamin D2
• Vitamin D3
• Calcium Supplements

By Route of Administration

• Oral
• Parental

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales
• Wholesale

• Retail (in-store)
• Distributors/ Franchises

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Hypoparathyroidism Treatment Market:

• Shire-NPS Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• EnteraBio Ltd.
• WCCT Global Inc.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc

Recent developments by key players in the Hypoparathyroidism Treatment Market:

Takeda Pharmaceutical Company Limited

• Manufacturing discontinuation and program wind-down: Takeda has announced that it will discontinue the manufacturing of NATPARA by the end of 2024 and will also wind down the U.S. Special Use Program. Shipments of NATPARA will cease by December 31, 2025, following an inventory depletion timeline. This removal from the market significantly opens opportunities for Ascendis and other companies.

Shire–NPS Pharmaceuticals (now Takeda)

• Developed Natpara (rhPTH[1-84]), approved by the FDA in 2015 for hypoparathyroidism.
• Now discontinued globally by Takeda (end of 2024) due to manufacturing issues.
• Shire’s role in this market has effectively ended after Takeda’s acquisition and product phase-out.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=11324&license=multi

**Objectives of this Study: **

1. To provide a comprehensive analysis of the Hypoparathyroidism Treatment Market By Drug Class, By Route of Administration, By Distribution Channel and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com

Article source: https://article-realm.com/article/Health-Fitness/78163-Hypoparathyroidism-Treatment-Market-2025-2033-Competitive-Landscape.html